Prospective Pilot study of Infliximab Dose-intensification determined by Capsule Endoscopic Evaluation of Small Intestinal Involvements in Patients with Crohn's Disease

Not Applicable

• Conditions: s disease; Crohn&#39

• Registration Number: JPRN-UMIN000012790
• Lead Sponsor: Saitama Medical center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-02-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

patients with contraindication of infliximab patients with pregnancy and lactation patients without informed consent patients under and after treatment of malignancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mucosal healing rates at 6 months

Secondary Outcome Measures

Name	Time	Method
mucosal healing rates at 12 months improvement of mucosal regions at 6 and 12 months serum CRP titer at 6 and 12 months stool calprotectin titer at 6 and 12 months stool PTX3 titer at 6 and 12 months safety